Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Hodgkin lymphoma
Ralf Küppers, … , Andreas Engert, Martin-Leo Hansmann
Ralf Küppers, … , Andreas Engert, Martin-Leo Hansmann
Published October 1, 2012
Citation Information: J Clin Invest. 2012;122(10):3439-3447. https://doi.org/10.1172/JCI61245.
View: Text | PDF
Category: Review Series

Hodgkin lymphoma

  • Text
  • PDF
Abstract

Hodgkin lymphoma (HL), a B cell–derived cancer, is one of the most common lymphomas. In HL, the tumor cells — Hodgkin and Reed-Sternberg (HRS) cells — are usually very rare in the tissue. Although HRS cells are derived from mature B cells, they have largely lost their B cell phenotype and show a very unusual co-expression of markers of various hematopoietic cell types. HRS cells show deregulated activation of multiple signaling pathways and transcription factors. The activation of these pathways and factors is partly mediated through interactions of HRS cells with various other types of cells in the microenvironment, but also through genetic lesions. The transforming events involved in the pathogenesis of HL are only partly understood, but mutations affecting the NF-κB and JAK/STAT pathways are frequent. The dependency of HRS cells on microenvironmental interactions and deregulated signaling pathways may offer novel strategies for targeted therapies.

Authors

Ralf Küppers, Andreas Engert, Martin-Leo Hansmann

×

Figure 1

Morphology and immunohistochemical features of HRS cells.

Options: View larger image (or click on image) Download as PowerPoint
Morphology and immunohistochemical features of HRS cells.
Typical histol...
Typical histological and immunohistochemical picture in classical HL. (A) H&E staining of a case of mixed cellularity type HL. A binucleated HRS cell is visible in the middle of the image, surrounded by histiocytes, lymphocytes, and eosinophilic granulocytes. (B) CD30 immunostaining (red) showing some large and small CD30-positive HRS cells. A binucleated HRS cell is visible in the middle of the image. HRS cells consistently express the TNF receptor family member CD30, so that immunostaining for CD30 is often used in the diagnosis of HL. (C) CD3 immunostaining showing large amounts of T cells that completely or partly surround HRS cells. Rosette forming T cells around a HRS cell in the middle of the image.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts